Transthyretin deposition in familial amyloidotic polyneuropathy

Current Medicinal Chemistry

Volumn 19, Issue 15, 2012, Pages 2304-2311

  Saraiva, M J ^a   Magalhaes, J ^a   Ferreira, N ^a   Almeida, M R ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Amyloidosis; Cytotoxicity; Familial amyloidotic polyneuropathy; Fibrillogenesis; Heat shock response; Neurodegenerative diseases; Transthyretin (TTR)

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARRIER PROTEIN; CASPASE 3; CURCUMIN; GELATINASE B; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK TRANSCRIPTION FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MEGALIN; METALLOTHIONEIN I; METALLOTHIONEIN II; NEUROPEPTIDE Y; PREALBUMIN; PROTEIN VARIANT; RETINOL; THYROID HORMONE; TUMOR NECROSIS FACTOR ALPHA;

ALPHA HELIX; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; AMYLOIDOSIS; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL FEATURE; CRYSTAL STRUCTURE; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DRUG BINDING; ENDOPLASMIC RETICULUM STRESS; EXTRACELLULAR MATRIX; FAMILIAL AMYLOID POLYNEUROPATHY; FAMILIAL AMYLOIDOSIS; GENE ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HEAT SHOCK RESPONSE; HUMAN; IMMUNOHISTOLOGY; LIPID PEROXIDATION; MACROPHAGE ACTIVATION; MEMBRANE FLUIDITY; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PREVALENCE; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RARE DISEASE; SCANNING TRANSMISSION ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 84860663436     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800269236     Document Type: Article

References (109)

1. Eanes, E. D.; Glenner, G.G. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem, 1968, 16, 673-677.
2. Sipe, J.D.; Benson, M.D.; Buxbaum, J.N.; Ikeda, S.I.; Merlini, G.; Saraiva, M.J.; Westermark, P. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid, 2010, 17,101-104.
3. Glenner, G.G.; Terry, W.; Harada, M.; Isersky, C.; Page, D. Amyloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analysis. Science, 1971, 172, 1150-1151.
4. Benditt, E.P.; Eriksen, N.; Hermodson, M.A.; Ericsson, L.H. The major proteins of human and monkey substance: Common properties including unusual N-terminal amino acid sequences. FEBS Letters, 1971, 19, 169-173.
5. Saraiva, M.J.; Birken, S.; Costa, P.P.; Goodman, D.S. Amyloid fibril protein in familialamyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest, 1984, 74(1), 104-119. (Pubitemid 14086050)
6. Soprano, D.R.; Herbert, J.; Soprano, K.J.; Schon, E.A.; Goodman, D.S. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem, 1985, 260(21),11793-11798. (Pubitemid 16250842)
7. Blake, C.C.; Geisow, M.J.; Oatley, S.J.; Rérat, B.; Rérat, C. Structure of prealbumin: Secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol. 1978, 21(3), 339-356. (Pubitemid 8361803)
8. Bartalena, L.; Robbins, J. Thyroid hormone transport proteins. Clin Lab Med, 1993, 13(3), 583-598. (Pubitemid 23267628)
9. Boomsma, F.; Manint Veld, A.J.; Schalekamp, M.A. Not norepinephrine but its oxidation products bind specifically to plasma proteins. J Pharmacol Exp Ther, 1991, 259(2), 551-557.
10. Ernström, U.; Pettersson, T.; Jörnvall, H. A yellow component associated with human transthyretin has properties like a pterin derivative,7,8-dihydropterin-6-carboxaldehyde. FEBS Lett, 1995, 360(2),177-182.
11. Martone, R.; Herbert, J. Transthyretin interacts with globin to form protein complexes with heme dependent solubility. J Rheumatol, 1993, 20, 176.
12. Smith, T.J.; Davis, F.B.; Deziel, M.R.; Davis, P.J.; Ramsden, D.B.; Schoenl, M. Retinoic acid inhibition of thyroxine binding to human transthyretin. Biochim Biophys Acta, 1994, 1199(1), 76-80. (Pubitemid 24022802)
13. Munro, S.L.; Lim, C.F.; Hall, J.G.; Barlow, J.W.; Craik, D.J.; Topliss, D.J.; Stockigt, J.R. Drug competition for thyroxine binding to transthyretin (prealbumin): Comparison with effects on thyroxine-binding globulin. J Clin Endocrinol Metab, 1989, 68(6),1141-1147. (Pubitemid 19144744)
14. Miroy, G.J.; Lai, Z.; Lashuel, H.A.; Peterson, S.A.; Strang, C.; Kelly, J.W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A, 1996, 93(26),15051-15056. (Pubitemid 27009550)
15. Peterson, S.A.; Klabunde, T.; Lashuel, H.A.; Purkey, H.; Sacchettini, J.C.; Kelly, J.W. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci U S A. 1998, 95(22),12956-12960. (Pubitemid 28509505)
16. McKinney, J.D.; Pedersen, L.G. Biological activity of polychlorinated biphenyls related to conformational structure. Biochem J, 1986, 240(2), 621-622. (Pubitemid 17196158)
17. Lans, M.C.; Klasson-Wehler, E.; Willemsen, M.; Meussen, E.; Safe, S.; Brouwer, A. Structure-dependent, competitive interaction of hydroxypolychlorobiphenyls,-dibenzo-p-dioxins and-dibenzofurans with human transthyretin. Chem Biol Interact, 1993, 88(1):7-21. (Pubitemid 23205415)
18. Davis, P.J.; Cody, V.; Davis, F.B.; Warnick, P.R.; Schoenl, M.; Edwards, L. Competition of milrinone, a non-iodinated cardiac inotropic agent, with thyroid hormone for binding sites on human serum prealbumin (TBPA). Biochem Pharmacol, 1987, 36, 3635-3640. (Pubitemid 18068314)
19. Köhrle, J.; Fang, S.L.; Yang, Y.; Irmscher, K.; Hesch, R.D.; Pino, S.; Alex, S.; Braverman, L.E. Rapid effects of the flavonoid EMD 21388 on serum thyroid hormone binding and thyrotropin regulation in the rat. Endocrinology, 1989, 125(1), 532-537. (Pubitemid 19182704)
20. Green, N.S.; Foss, T.R.; Kelly, J.W. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci USA, 2005, 102(41),14545-14550. (Pubitemid 41457094)
21. Radovic, B.; Mentrup, B.; Köhrle, J. Genistein and other soya isoflavones are potent ligands for transthyretin in serum and cerebrospinal fluid. Br J Nutr, 2006, 95(6), 1171-1176. (Pubitemid 43985997)
22. Klabunde, T.; Petrassi, H.M.; Oza, V.B.; Raman, P.; Kelly, J.W.; Sacchettini, J.C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol, 2000, 7(4), 312-321. (Pubitemid 30194456)
23. Commodari, F.; Khiat, A.; Ibrahimi, S.; Brizius, A.R.; Kalkstein, N. Comparison of the phytoestrogen trans-resveratrol (3,4',5-trihydroxystilbene) structures from x-ray diffraction and solution NMR. Magn Reson Chem. 2005, 43(7), 567-572. (Pubitemid 40840290)
24. Maia, F.; Almeida, M.R.; Gales, L.; Kijjoa, A.; Pinto, M.M.; Saraiva, M.J.; Damas, A.M. The binding of xanthone derivatives to transthyretin. Biochem Pharmacol, 2005, 70(12), 1861-1869. (Pubitemid 41612017)
25. Ferreira, N.; Cardoso, I.; Domingues, M.R.; Vitorino, R.; Bastos, M.; Bai, G.; Saraiva, M.J.; Almeida M.R. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett, 2009, 583,3569-3576.
26. Miyata, M.; Sato, T.; Kugimiya, M.; Sho, M.; Nakamura, T.; Ikemizu, S.; Chirifu, M.; Mizuguchi, M.; Nabeshima, Y.; Suwa, Y.; Morioka, H.; Arimori, T.; Suico, M.A.; Shuto, T.; Sako, Y.; Momohara, M.; Koga, T.; Morino-Koga, S.; Yamagata, Y.; Kai, H. The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Biochemistry, 2010, 49(29), 6104-6114.
27. Pullakhandam, R.; Srinivas, P.N.; Nair, M.K.; Reddy, G.B. Binding and stabilization of transthyretin by curcumin. Arch Biochem Biophys, 2009, 485(2), 115-119.
28. Ferreira, N.; Saraiva, M.J.; Almeida, M.R. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett, 2011, 585(15), 2424-2430.
29. Goodman, D.S. Retinoids and retinol binding protein. In: The Harvey lectures, Series 81, 111, 1987.
30. Naylor, H.M.; Newcomer, M.E. The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. Biochemistry. 1999, 38(9), 2647-2653.
31. Hyung, S.J.; Deroo, S.; Robinson, C.V. Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex. ACS Chem Biol, 2010, 5(12), 1137-1146.
32. Sousa, M.M.; Berglund, L.; Saraiva, M.J. Transthyretin in high density lipoproteins: Association with apolipoprotein A-I. J Lipid Res, 2000, 41(1), 58-65. (Pubitemid 30051842)
33. Liz, M.A.; Faro, C.J; Saraiva, M.J.; Sousa, M.M. Transthyretin, a new cryptic protease. J Biol Chem, 2004, 279(20), 21431-21438.
34. Liz, M.A.; Gomes, C.M.; Saraiva, M.J.; Sousa, M.M. ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J Lipid Res, 2007, 48(11), 2385-2395. (Pubitemid 350058750)
35. Liz, M.A.; Fleming, C.E.; Nunes, A.F.; Almeida, M.R.; Mar, F.M.; Choe, Y.; Craik, C.S.; Powers, J.C.; Bogyo, M.; Sousa, M.M. Substrate specificity of transthyretin: Identification of natural substrates in the nervous system. Biochem J, 2009, 419(2), 467-474.
36. Sousa, M.M.; Norden, A.G.; Jacobsen, C.; Willnow, T.E.; Christensen, E.I.; Thakker, R.V.; Verroust, P.J.; Moestrup, S.K.; Saraiva, M.J. Evidence for the role of megalin in renal uptake of transthyretin. J Biol Chem, 2000, 275(49), 38176-38181. (Pubitemid 32009135)
37. Sousa, M.M.; Yan, S.D.; Stern, D.; Saraiva, M.J. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest, 2000, 80(7), 1101-1110. (Pubitemid 30483229)
38. Monteiro, F.A.; Cardoso, I.; Sousa, M.M.; Saraiva, M.J. In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Lett, 2006, 580(14), 3451-3456. (Pubitemid 43795891)
39. Schwarzman, A.L.; Gregori, L.; Vitek, M.P.; Lyubski, S.; Strittmatter, W.J.; Enghilde, J.J.; Bhasin, R.; Silverman, J.; Weisgraber, K.H.; Coyle, P.K.; et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A, 1994, 91(18), 8368-8372. (Pubitemid 24273665)
40. Merched, A.; Serot, J.M.; Visvikis, S.; Aguillon, D.; Faure, G.; Siest, G. Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: Relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett, 1998, 425(2), 225-228. (Pubitemid 28178895)
41. Choi, S.H.; Leight, S.N.; Lee, V.M.; Li, T.; Wong, P.C.; Johnson, J.A.; Saraiva, M.J.; Sisodia, S.S. Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci, 2007, 27(26), 7006-7010. (Pubitemid 47015887)
42. Costa, R.; Gonçalves, A.; Saraiva, M.J.; Cardoso, I. Transthyretin binding to A-Beta peptide-impact on A-Beta fibrillogenesis and toxicity. FEBS Lett, 2008, 582(6), 936-942.
43. Costa, R.; Ferreira-da-Silva, F.; Saraiva, M.J.; Cardoso I. Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: A mechanism sensitive to the Kunitz protease inhibitor. PLoS One, 2008, 3(8):e2899.
44. Gonçalves, I.; Quintela, T.; Baltazar, G.; Almeida, M.R.; Saraiva, M.J.; Santos, C.R. Transthyretin interacts with metallothionein 2. Biochemistry, 2008, 47(8), 2244-2251. (Pubitemid 351304532)
45. Martinho, A.; Gonçalves, I.; Cardoso, I.; Almeida, M.R.; Quintela, T.; Saraiva, M.J.; Santos, C.R. Human metallothioneins 2 and 3 differentially affect amyloid-beta binding by transthyretin. FEBS J, 2010, 277(16), 3427-3436.
46. Westermark, P.; Sletten, K.; Johansson, B.; Cornwell, G.G. 3rd. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A, 1990, 87(7), 2843-2845.
47. Sasaki, H; Sakaki, Y.; Matsuo, H.; Goto, I.; Kuroiwa, Y.; Sahashi, I.; Takahashi, A.; Shinoda, T.; Isobe, T.; Takagi, Y. Diagnosis of familial amyloidotic polyneuropathy by recombinant DNA techniques. Biochem Biophys Res Commun, 1984, 125(2), 636-642. (Pubitemid 15155744)
48. Andrade, C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain, 1952, 75(3), 408-427.
49. Dwulet, F.E.; Benson, M.D. Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc Natl Acad Sci U S A, 1984, 81(3), 694-698. (Pubitemid 14199012)
50. Nakazato, M.; Kurihara, T.; Kangawa, K.; Matsuo, H. Diagnostic radioimmunoassay for familial amyloidotic polyneuropathy. Lancet, 1984, 2(8414), 1274-1275. (Pubitemid 15217737)
51. Ferlini, A.; Romeo, G.; Tassinari, C.A.; Saraiva, M.J.; Costa, P.P.; Salvi, F. Discrimination of peripheral polyneuropathies caused by TTR variant or diabetes in the same pedigree through protein studies. Adv Neurol, 1988, 48:201-208.
52. Munar-Qués, M.; Pedrosa, J.L.; Coelho, T.; Gusmão, L.; Seruca, R.; Amorim, A.; Sequeiros, J. Two pairs of proven monozygotic twins discordant for familial amyloid neuropathy (FAP) TTR Met 30. J Med Genet, 1999, 36(8), 629-632. (Pubitemid 29368905)
53. Holt, I.J.; Harding, A.E.; Middleton, L.; Chrysostomou, G.; Said, G.; King, R.H.M.; Thomas, P.K. Molecular genetics of amyloid neuropathy in Europe. Lancet, 1989, 333, 524-526. (Pubitemid 19075207)
54. Jacobson, D.R.; McFarlin, D.E.; Kane, I.; Buxbaum, J.N. Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum Genet. 1992, 89(3), 353-356.
55. Jacobson, D.R.; Pastore, R.; Pool, S.; Malendowicz, S.; Kane, I.; Shivji, A.; Embury, S.H.; Ballas, S.K.; Buxbaum, J.N. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet, 1996, 98(2):236-8. (Pubitemid 26237513)
56. Brett, M.; Persey, M.R.; Reilly, M.M.; Revesz, T.; Booth, D.R.; Booth, S.E.; Hawkins, P.N.; Pepys, M.B.; Morgan-Hughes, J.A. Transthyretin Leu12Pro is associated with systemic,neuropathic and leptomeningeal amyloidosis. Brain, 1999, 122( Pt 2), 183-190. (Pubitemid 29067201)
57. Vidal, R.; Garzuly, F.; Budka, H.; Lalowski, M.; Linke, R.P.; Brittig, F.; Frangione, B.; Wisniewski, T. Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G). Am J Pathol, 1996, 148(2), 361-366. (Pubitemid 26056720)
58. Gorevic, P.D.; Prelli, F.C.; Wright, J.; Pras, M.; Frangione, B. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: Immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J Clin Invest, 1989, 83(3), 836-843. (Pubitemid 19080614)
59. Saraiva, M.J.; Costa, P.P. Molecular biology of the amyloidogenesis in the transthyretin related amyloidoses. In: Amyloid and Amyloidosis. Natvig JB, Forre O, Husby G, et al (eds), Doordrecht, The Netherlands: Kluwer Academic Publishers, 1991, 569-574.
60. Gustavsson, A.; Jahr, H.; Tobiassen, R.; Jacobson, D.R.; Sletten, K.; Westermark, P. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Lab Invest, 1995, 73(5), 703-708.
61. Bergström, J.; Gustavsson, A.; Hellman, U.; Sletten, K.; Murphy, C.L.; Weiss, D.T.; Solomon, A.; Olofsson, B.O.; Westermark, P. Amyloid deposits in transthyretin-derived amyloidosis: Cleaved transthyretin is associated with distinct amyloid morphology. J Pathol, 2005, 206(2), 224-232. (Pubitemid 40754027)
62. Ihse, E.; Ybo, A.; Suhr, O.; Lindqvist, P.; Backman, C.; Westermark, P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol, 2008, 216(2):253-261.
63. Alves, IL.; Altland, K.; Almeida, M.R.; Winter, P.; Saraiva, M.J. Screening and biochemical characterization of transthyretin variants in the Portuguese population. Hum Mutat, 1997, 9, 226-233. (Pubitemid 27138815)
64. Longo Alves, I.; Hays, M.T.; Saraiva, M.J. Comparative stability and clearance of [Met30] transthyretin and [Met119] transthyretin. Eur J Biochem. 1997, 249(3), 662-668. (Pubitemid 27479035)
65. Kelly, J.W.; Lansbury, P.T. Jr. A chemical approach to elucidate the mechanism of transthyretin and beta-protein amyloid fibril formation. Amyloid: Int J Exp Clin Invest, 1994, 1, 186-205. (Pubitemid 2152062)
66. Bonifácio, M.J.; Sakaki, Y.; Saraiva, M.J. 'In vitro' amyloid fibril formation from transthyretin: The influence of ions and the amyloidogenicity of TTR variants. Biochim Biophys Acta, 1996, 1316(1), 35-42. (Pubitemid 26173904)
67. Brito, R.; Damas, A.M.; Saraiva, M.J. Amyloid Formation by Transthyretin: From Protein Stability to Protein Aggregation. Curr. Med. Chem.-Immun. Endoc. & Metab. Agents, 2003, 3, 349.
68. Sebastião, M.P.; Saraiva, M.J.; Damas, A.M.; The crystal structure of amyloidogenic Leu55Pro Transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils, J Biol Chem, 1998, 273, 24715-24722. (Pubitemid 28454972)
69. Sebastião, M.P.; Lamzin, V.; Saraiva, M.J.; Damas, A.M. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. J Mol Biol, 2001, 306(4), 733-744. (Pubitemid 33027696)
70. Inouye, H.; Domingues, F.S.; Damas, A.M.; Saraiva, M.J.; Lundgren, E.; Sandgren, O.; Kirschner, D.A. Analysis of x-ray diffraction patterns from amyloid of biopsied vitreous humor and kidney of transthyretin (TTR) Met30 familial amyloidotic polyneuropathy (FAP) patients: Axially arrayed TTR monomers constitute the protofilament. Amyloid, 1998, 5(3), 163-174. (Pubitemid 128699444)
71. Cardoso, I.; Goldsbury, S.A.; Muller, V.; Olivieri, S.; Wirtz, S.; Damas, A.M.; Aebi, U. Saraiva, M.J. Transthyretin fibrillogenesis entails the assembly of monomers: A molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Mol Biol, 2002, 317, 683-695. (Pubitemid 34722157)
72. Quintas, A.; Saraiva, M.J.; Brito, R.M.M. The tetrameric protein transthyretin dissociates to a non-native monomer in solution. J Biol Chem, 1999, 274, 32943-32949. (Pubitemid 129535333)
73. Quintas, A.; Vaz, D.C.; Cardoso, I.; Saraiva, M.; Brito, R.M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem, 2001, 276, 27207-27213.
74. Cendron, L.; Trovato, A.; Seno, F.; Folli, C.; Alfieri, B.; Zanotti, G.; Berni, R. Amyloidogenic potential of transthyretin variants: Insights from structural and computational analyses.J Biol Chem. 2009, 284(38), 25832-2584.
75. Rodrigues, J.R.; Simões, C.J.; Silva, C.G.; Brito, R.M.; Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: Insights from molecular dynamics simulations. Protein Sci. 2010, 19(2), 202-219.
76. Miroy, G.J.; Lai, Z.; Lashuel, H.A.; Peterson, S.A.; Strang, C.; Kelly, J.W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A, 1996, 93(26),15051-15056. (Pubitemid 27009550)
77. Cardoso, I.; Almeida, M.R.; Ferreira, N.; Arsequell, G.; Valencia, G.; Saraiva, M.J. Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: Relevance in drug design. Biochem J, 2007, 408(1), 131-138. (Pubitemid 350158411)
78. Bieschke, J.; Russ, J.; Friedrich, R.P.; Ehrnhoefer, D.E.; Wobst, H.; Neugebauer, K.; Wanker, E.E. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A, 2010, 107(17), 7710-7715.
79. Araki, S.; Yi, S.; Murakami, T.; Watanabe, S.; Ikegawa, S.; Takahashi, K.; Yamarnura, K. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met 30) gene. Pathological and immunohistochemical similarity to human familial amyloidotic polyneuropathy, type I. Mol Neurobiol, 1994, 8,15-23.
80. Yi, S.; Takahashi, K.; Naito, M.; Tashiro, F.; Wakasugi, S.; Maeda, S.; Shimada, K.; Yamamura, K.; Araki, S. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I. Am J Pathol. 1991, 138, 403-412.
81. Kohno, K.; Palha, J.A.; Miyakawa, K.; Saraiva, M.J.; Ito, S.; Mabuchi, T.; Blaner, W.S.; Iijima, H.; Tsukahara, S.; Episkopou, V.; et al. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol, 1997, 150, 1497-1508. (Pubitemid 27152666)
82. Cardoso, I.; Merlini, G.; Saraiva, M.J. 4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: Screening for TTR fibril disrupters. , 2003, 17(8), 803-809.
83. Cardoso, I.; Saraiva, M.J. Doxycycline disrupts transthyretin amyloid: Evidence from studies in a FAP transgenic mice model. FASEB J, 2006, 20(2), 234-239. (Pubitemid 44933170)
84. Teng, M.; Gallo, G.; Buxbaum, J. Is an amyloidogenic substrate enough? Transgenic mice producing human TTR Pro55 do not develop amyloid. Neuromuscul Disord, 1995, 6,S48
85. Waits, R.; Uemichi, T.; Zekdenrust, S.; Hull, M.; Field, L.; Benson, M. Development of lines of transgenic mice expressing the human transthyretin Ser84 variant. Neuromuscul Disord, 1995, 6:S31
86. Sousa, M.M.; Fernandes, R.; Palha, J.A.; Taboada, A.; Vieira, P.; Saraiva, M.J. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol, 2002, 161:1935-1948. (Pubitemid 35265550)
87. Santos, S.D.; Fernandes, R.; Saraiva, M.J. The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. Neurobiol Aging, 2010, 31, 280-289.
88. Teng, M.H.; Yin, J.Y.; Vidal, R.; Ghiso, J.; Kumar, A.; Rabenou, R.; Shah, A.; Jacobson, D.R.; Tagoe, C.; Gallo, G.; Buxbaum, J. Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: A possible model for senile systemic amyloidosis. Lab Invest. 2001, 81, 385-396. (Pubitemid 32245070)
89. Coimbra, A.; Andrade, C. (1971). Familial amyloid polyneuropathy: An electron microscope study of the peripheral nerve in five cases. I. Interstitial changes. Brain, 1971, 94, 199-206.
90. Sousa, M.M.; Cardoso, I.; Fernandes, R.; Guimaraes, A.; Saraiva, M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: Evidence for toxicity of nonfibrillar aggregates. Am J Pathol, 2001, 159, 1993-2000. (Pubitemid 33104254)
91. Andersson, K.; Olofsson, A.; Nielsen, E.H.; Svehag, S.E.; Lundgren, E. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun, 2002, 294, 309-314. (Pubitemid 34694094)
92. Hou, X.; Richardson, S.J.; Aguilar, M.I.; Small, D.H. Binding of amyloidogenic transthyretin to the plasma membrane alters membrane fluidity and induces neurotoxicity. Biochemistry, 2005, 44, 11618-11627. (Pubitemid 41209098)
93. Sousa, M.M.; Du Yan, S.; Fernandes, R.; Guimaraes, A.; Stern, D.; Saraiva, M.J. Familial amyloid polyneuropathy: Receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci, 2001, 21, 7576-7586. (Pubitemid 32904957)
94. Macedo, B.; Batista, A.R.; do Amaral, J.B.; Saraiva, M.J. Biomarkers in the assessment of therapies for familial amyloidotic polyneuropathy. Mol Med, 2007, 13, 584-591. (Pubitemid 350228719)
95. Lindholm, D.; Wootz, H.; Korhonen, L. ER stress and neurodegenerative diseases. Cell Death Differ, 2006, 13, 385-392.
96. Teixeira, P.F.; Cerca, F.; Santos, S.D.; Saraiva, M.J. Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy. J Biol Chem, 2006, 281, 21998-22003. (Pubitemid 44181903)
97. Veerhuis, R.; Janssen, I.; De Groot, CJ.; Van Muiswinkel, F.L.; Hack, C.E.; Eikelenboom, P. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Exp Neurol, 1999, 160, 289-299.
98. Nakamura, Y.; Yutani, C.; Nakazato, M.; Date, Y.; Baba, T.; Goto, Y. A case of hereditary amyloidosis transthyretin variant Met 30 with amyloid cardiomyopathy, less polyneuropathy, and the presence of giant cells. Pathol Int, 1999, 49,898-902.
99. Tofaris, G.K.; Patterson, P.H.; Jessen, K.R.; Mirsky, R. Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J Neurosci, 2002, 22, 6696-6703. (Pubitemid 35386425)
100. Ando, Y.; Nyhlin, N.; Suhr, O.; Holmgren, G.; Uchida, K.; el Sahly, M.; Yamashita, T.; Terasaki, H.; Nakamura, M.; Uchino, M.; Ando, M. Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem Biophys Res Commun, 1997, 232, 497-502. (Pubitemid 27216247)
101. Santos, S.D.; Magalhaes, J.; Saraiva, M.J. Activation of the heat shock response in familial amyloidotic polyneuropathy. J Neuropathol Exp Neurol, 2008, 67, 449-455. (Pubitemid 351653536)
102. Magalhaes, J.; Santos, S.D.; Saraiva, M.J. alphaB-crystallin (HspB5) in familial amyloidotic polyneuropathy. Int J Exp Pathol, 2010, 91, 515-521.
103. Santos, S.D.; Cardoso, I.; Magalhaes, J.; Saraiva, M.J. Impairment of the ubiquitin-proteasome system associated with extracellular transthyretin aggregates in familial amyloidotic polyneuropathy. J Pathol, 2007, 213, 200-209. (Pubitemid 47612242)
104. Beere, H.M. Death versus survival: Functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest, 2005, 115, 2633-2639. (Pubitemid 41434386)
105. Concannon, C.G.; Gorman, A.M.; Samali, A. On the role of Hsp27 in regulating apoptosis. Apoptosis, 2003, 8, 61-70. (Pubitemid 36133139)
106. Mehlen, P.; Hickey, E.; Weber, L.A.; Arrigo, A.P. Large unphosphorylated aggregates as the active form of hsp27 which controls intracellular reactive oxygen species and glutathione levels and generates a protection against TNFalpha in NIH-3T3-ras cells. Biochem Biophys Res Commun, 1997, 241, 187-192. (Pubitemid 28033560)
107. Rogalla, T.; Ehrnsperger, M.; Preville, X.; Kotlyarov, A.; Lutsch, G.; Ducasse, C.; Paul, C.; Wieske, M.; Arrigo, A.P.; Buchner, J.; Gaestel, M. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem, 1999, 274, 18947-18956.
108. Sousa, M.M.; do Amaral J.B.; Guimarães, A.; Saraiva, M.J. Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinaseassociated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J, 2005, 19(1), 124-126. (Pubitemid 40069939)
109. Cardoso, I.; Brito, M.; Saraiva, M.J. Extracellular matrix markers for disease progression and follow-up of therapies in familial amyloid polyneuropathy V30M TTR-related. Dis Markers, 2008, 25(1), 37-47.